Literature DB >> 16848419

Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.

Ganesan Vaidyanathan1, Kevin L Alston, Darrel D Bigner, Michael R Zalutsky.   

Abstract

Novel methods are needed for the radiohalogenation of cell-internalizing proteins and peptides because rapid loss of label occurs after lysosomal processing when these molecules are labeled using conventional radioiodination methodologies. We have developed a radiolabeled prosthetic group that contains multiple negatively charged D-amino acids to facilitate trapping of the radioactivity in the cell after proteolysis of the labeled protein. N(epsilon)-(3-[(125)I]iodobenzoyl)-Lys(5)-N(alpha)-maleimido-Gly(1)-GEEEK ([(125)I]IB-Mal-D-GEEEK) was synthesized via iododestannylation in 90.3 +/- 3.9% radiochemical yields. This radioiodinated agent was conjugated to iminothiolane-treated L8A4, an anti-epidermal growth factor receptor variant III (EGFRvIII) specific monoclonal antibody (mAb) in 54.3 +/- 17.7% conjugation yields. In vitro assays with the EGFRvIII-expressing U87MGDeltaEGFR glioma cell line demonstrated that the internalized radioactivity for the [(125)I]IB-Mal-D-GEEEK-L8A4 conjugate increased from 14.1% at 1 h to 44.7% at 24 h and was about 15-fold higher than that of directly radioiodinated L8A4 at 24 h. A commensurately increased tumor uptake in vivo in athymic mice bearing subcutaneous U87MGDeltaEGFR xenografts (52.6 +/- 14.3% injected dose per gram versus 17.4 +/- 3.5% ID/g at 72 h) also was observed. These results suggest that [(125)I]IB-Mal-d-GEEEK is a promising reagent for the radioiodination of internalizing mAbs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848419     DOI: 10.1021/bc0600766

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  16 in total

1.  Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Authors:  Michael R Zalutsky; Abraham Boskovitz; Chien-Tsun Kuan; Charles N Pegram; Joanne Ayriss; Carol J Wikstrand; Anne F Buckley; Eric S Lipp; James E Herndon; Roger E McLendon; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

2.  Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.

Authors:  Marc Hens; Ganesan Vaidyanathan; Phil Welsh; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

3.  Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.

Authors:  Jaeyeon Choi; Ganesan Vaidyanathan; Eftychia Koumarianou; Choong Mo Kang; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2017-09-19       Impact factor: 2.408

Review 4.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

5.  Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; H Kim Lyerly; Michael R Zalutsky
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

6.  SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.

Authors:  G Vaidyanathan; B J White; D J Affleck; X G Zhao; P C Welsh; D McDougald; J Choi; M R Zalutsky
Journal:  Bioorg Med Chem       Date:  2012-10-29       Impact factor: 3.641

7.  Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-11-15       Impact factor: 2.408

8.  Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.

Authors:  Ganesan Vaidyanathan; Emmanuelle Jestin; Tove Olafsen; Anna M Wu; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

9.  N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Marek Pruszynski; Eftychia Koumarianou; Zhengyuan Zhou; Michael R Zalutsky
Journal:  Org Biomol Chem       Date:  2015-12-08       Impact factor: 3.876

10.  D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Satish Chitneni; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-08-13       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.